Pharmaceutical Statistics

Cover image for Vol. 13 Issue 2

Editors-in-Chief: Oliver Keene, Lisa LaVange and Gerd Rosenkranz

Impact Factor: 0.99

ISI Journal Citation Reports © Ranking: 2012: 50/117 (Statistics & Probability); 206/261 (Pharmacology & Pharmacy)

Online ISSN: 1539-1612

Recently Published Issues

See all

Pharmaceutical Statistics OnlineOpen

OnlineOpen – The Open Access Option for Authors

OnlineOpen is available to authors who wish to make their article open access, free to read, download and share via Wiley Online Library and PubMed Central. Read this recent OnlineOpen article. Yours can be too. Learn more about OnlineOpen.

Escalation strategies for combination therapy Phase I trials
Michael J. Sweeting and Adrian P. Mander

 Pharmaceutical Statistics OnlineOpen

PSI's Pharmaceutical Statistics Journal Club

The latest PSI and RSS Virtual Journal Club Meeting, sponsored by Wiley and Quintiles, was on Combination Therapies and their evaluation during early phase trials. The event took place on 1st April, with two speakers presenting their papers; Ying Yuan (University of Texas) and Michael Sweeting (University of Cambridge).

Chair: James Carpenter, School of Hygiene and Tropical Medicine

Speaker: Ying Yuan, Department of Biostatistics, University of Texas
A Bayesian dose finding design for oncology clinical trials of combinational biological agents
Journal of the Royal Statistical Society: Series C (Applied Statistics), Volume 63, Issue 1

Speaker: Michael J Sweeting, Department of Public Health and Primary Care, University of Cambridge
Escalation strategies for combination therapy Phase I trials
Pharmaceutical Statistics, Volume 11, Issue 3

Full details are available at

Archive of previous Journal Club meetings

Pharmaceutical Statistics

New Editor-in-Chief

We are delighted to welcome Gerd Rosenkranz as one of three Editors-in-Chief of Pharmaceutical Statistics. After completing an MSc in mathematics and physics, Gerd joined the departments of Biostatistics and Mathematical Modeling at the German Cancer Research Center and received a PhD in mathematics.

He has more that 25 years experience within the pharmaceutical industry, from pre-clinical research work at Hoechst (now Sanofi-Aventis) to clinical development (vaccines, oncology, and recently neuroscience) at Sandoz/Novartis in Basel. He has also published in the areas of safety analysis and missing data, among other topics.

Don't Miss the Latest Pharmaceutical Statistics Special Issue

Pharmaceutical Statistics Special Issue

Special Issue: Focusing on the PSI Special Interest Groups